{"id":1263,"date":"2023-06-14T19:12:34","date_gmt":"2023-06-14T17:12:34","guid":{"rendered":"https:\/\/centrosviluppofarmaci-opbg.it\/trial\/pid-ped-study-kb070\/"},"modified":"2024-02-08T09:45:16","modified_gmt":"2024-02-08T08:45:16","slug":"pid-ped-study-kb070","status":"in-corso","type":"trial","link":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/","title":{"rendered":"PID-PED study KB070"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)<\/p>\n","protected":false},"author":1,"featured_media":0,"menu_order":0,"template":"","meta":{"footnotes":""},"trials_category":[66],"scope":[55],"class_list":["post-1263","trial","type-trial","status-in-corso","hentry","trials_category-profit-en","scope-clinical-immunology-and-vaccinology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PID-PED study KB070 - Centro Sviluppo Farmaci<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PID-PED study KB070 - Centro Sviluppo Farmaci\" \/>\n<meta property=\"og:description\" content=\"A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/\" \/>\n<meta property=\"og:site_name\" content=\"Centro Sviluppo Farmaci\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-08T08:45:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/pid-ped-study-kb070\\\/\",\"url\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/pid-ped-study-kb070\\\/\",\"name\":\"PID-PED study KB070 - Centro Sviluppo Farmaci\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/#website\"},\"datePublished\":\"2023-06-14T17:12:34+00:00\",\"dateModified\":\"2024-02-08T08:45:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/pid-ped-study-kb070\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/pid-ped-study-kb070\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/pid-ped-study-kb070\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/homepage\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PID-PED study KB070\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/\",\"name\":\"Centro Sviluppo Farmaci\",\"description\":\"Insieme, facciamo crescere l\u2019innovazione.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PID-PED study KB070 - Centro Sviluppo Farmaci","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/","og_locale":"en_US","og_type":"article","og_title":"PID-PED study KB070 - Centro Sviluppo Farmaci","og_description":"A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)","og_url":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/","og_site_name":"Centro Sviluppo Farmaci","article_modified_time":"2024-02-08T08:45:16+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/","url":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/","name":"PID-PED study KB070 - Centro Sviluppo Farmaci","isPartOf":{"@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/#website"},"datePublished":"2023-06-14T17:12:34+00:00","dateModified":"2024-02-08T08:45:16+00:00","breadcrumb":{"@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/homepage\/"},{"@type":"ListItem","position":2,"name":"PID-PED study KB070"}]},{"@type":"WebSite","@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/#website","url":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/","name":"Centro Sviluppo Farmaci","description":"Insieme, facciamo crescere l\u2019innovazione.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"related_news":null},"card_html":"\n<div class=\"card card-trial\">\n    <div class=\"card-body\">\n        <h4 class=\"card-title\">PID-PED study KB070<\/h4>\n        <p>A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)<\/p>\n                    <div class=\"trials-category\">\n                                    <button class=\"btn btn-outline-primary profit-en\">\n                        Profit                    <\/button>\n            <\/div>\n                <a href=\"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/pid-ped-study-kb070\/\" title=\"Show more\" class=\"link-secondary\">\n            <svg class=\"icon\"><use xlink:href=\"https:\/\/centrosviluppofarmaci-opbg.it\/wp-content\/themes\/csf\/assets\/dist\/svg\/sprite-icon.svg#icon-arrow-right\"><\/use><\/svg>\n        <\/a>\n    <\/div>\n    <div class=\"card-footer d-grid gap-2\">\n\t                <span class=\"btn btn-outline-primary\">\n\t\t\t    Trial in progress            <\/span>\n\t    \t                <button class=\"btn btn-outline-secondary\" data-bs-toggle=\"modal\" data-bs-target=\"#contactEModal\" data-bs-trial=\"PID-PED study KB070\">\n\t\t\t    Contact us for enrollment            <\/button>\n\t            <button class=\"btn btn-outline-secondary\" data-bs-toggle=\"modal\" data-bs-target=\"#contactIModal\" data-bs-trial=\"PID-PED study KB070\">\n\t\t    Contact us for information        <\/button>\n\t        <\/div>\n<\/div>\n","_links":{"self":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trial\/1263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trial"}],"about":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/types\/trial"}],"author":[{"embeddable":true,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trial\/1263\/revisions"}],"predecessor-version":[{"id":1648,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trial\/1263\/revisions\/1648"}],"wp:attachment":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/media?parent=1263"}],"wp:term":[{"taxonomy":"trials_category","embeddable":true,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trials_category?post=1263"},{"taxonomy":"scope","embeddable":true,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/scope?post=1263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}